Skip to content

BIOSCIENCE HEALTH INNOVATIONS INC.: 10-Q filed 2025-10-27

What BIOSCIENCE HEALTH INNOVATIONS INC. reported in its quarterly report filed 2025-10-27 (fiscal Q3 2025): 35 published measures, 104 facts as tagged in accession 0001185185-25-001545.

This filing

Form
10-Q (quarterly report)
Filed
2025-10-27
Fiscal period
fiscal Q3 2025
Accession
0001185185-25-001545 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOSCIENCE HEALTH INNOVATIONS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-302,067,100USD
At 2024-12-31873,788USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-30356,140USD
At 2024-12-3138,548USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-301,710,960USD
At 2025-06-301,719,742USD
At 2025-03-311,262,038USD
At 2024-12-31835,240USD
At 2024-09-30370,283USD
At 2024-06-30189,081USD
At 2024-03-31114,859USD
At 2023-12-31-6,760USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-301,139,423USD
At 2024-12-31662,517USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-8,782USD92
2025-01-01 to 2025-09-30875,720USD273
2025-04-01 to 2025-06-30457,704USD91
2025-01-01 to 2025-03-31426,798USD90
2024-07-01 to 2024-09-3056,202USD92
2024-01-01 to 2024-09-3077,043USD274
2024-04-01 to 2024-06-3074,222USD91
2024-01-01 to 2024-03-31-53,381USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30272,874USD273
2024-01-01 to 2024-09-3073,493USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,131,427USD92
2025-01-01 to 2025-09-304,115,960USD273
2024-07-01 to 2024-09-30572,973USD92
2024-01-01 to 2024-09-301,234,744USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-30250,096USD273
2024-01-01 to 2024-09-30247,526USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-46,064USD273
2024-01-01 to 2024-09-30-7,037USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30534,637USD
At 2024-12-31-341,083USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3010,979,055shares92
2025-01-01 to 2025-09-3010,979,055shares273
2024-07-01 to 2024-09-3010,474,055shares92
2024-01-01 to 2024-09-3010,386,008shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3010,979,055shares92
2025-01-01 to 2025-09-3011,399,055shares273
2024-07-01 to 2024-09-3010,894,055shares92
2024-01-01 to 2024-09-3010,806,008shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-300USD/shares92
2025-01-01 to 2025-09-300.08USD/shares273
2024-07-01 to 2024-09-300.01USD/shares92
2024-01-01 to 2024-09-300.01USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-300USD/shares92
2025-01-01 to 2025-09-300.08USD/shares273
2024-07-01 to 2024-09-300.01USD/shares92
2024-01-01 to 2024-09-300.01USD/shares274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-8,782USD92
2025-01-01 to 2025-09-30875,720USD273
2024-07-01 to 2024-09-3056,202USD92
2024-01-01 to 2024-09-3077,043USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-301,994,999USD
At 2024-12-31847,751USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-3010,165USD
At 2024-12-318,226USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-3063,212USD
At 2024-12-31100,285USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-30707,013USD92
2025-01-01 to 2025-09-301,793,134USD273
2024-07-01 to 2024-09-30368,538USD92
2024-01-01 to 2024-09-30892,836USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-30757,500USD
At 2024-12-3158,319USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30698,231USD92
2025-01-01 to 2025-09-302,668,854USD273
2024-07-01 to 2024-09-30424,740USD92
2024-01-01 to 2024-09-30969,879USD274

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-07-01 to 2025-09-30576,656USD92
2025-01-01 to 2025-09-301,550,291USD273
2024-07-01 to 2024-09-30345,288USD92
2024-01-01 to 2024-09-30846,236USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-01-01 to 2025-09-3066,372USD273
2024-01-01 to 2024-09-3029,808USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3010,979,055shares
At 2024-12-3110,979,055shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-301,139,423USD
At 2024-12-31662,517USD
At 2024-09-30333,220USD
At 2023-12-3119,238USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-301,175,211USD
At 2024-12-311,175,211USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-09-3072,101USD
At 2024-12-3126,037USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-306,686USD
At 2024-12-315,993USD

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-01-01 to 2024-12-310USD366
2023-01-01 to 2023-12-310USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-300USD273
2024-01-01 to 2024-09-300USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-01-01 to 2025-09-300USD273
2024-01-01 to 2024-09-300USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-09-300USD273
2024-07-01 to 2024-09-30175,000USD92
2024-01-01 to 2024-09-30300,000USD274
2024-01-01 to 2024-03-31175,000USD91

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-37,073USD273
2024-01-01 to 2024-09-30-4,535USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30699,181USD273
2024-01-01 to 2024-09-304,523USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,939USD273
2024-01-01 to 2024-09-30772USD274

Inspect the source

Entity
BIOSCIENCE HEALTH INNOVATIONS INC. / CIK 0001784440
Captured
2026-09-21T17:27:18.355Z
SEC response SHA-256
258389c2272219709f8af0bab4503ee09fd51f4fbb1b223238028a2471bb5cb8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001784440.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))